Trial Profile
A Randomized, Multicenter, Open-Label Cross-Over Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Patients With HER2-Positive Early Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Pertuzumab/trastuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Inflammatory breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms PHranceSCa
- Sponsors Roche
- 21 Oct 2023 This trial has been completed in Spain according to European Clinical Trials Database record.
- 25 Sep 2023 According to a Chugai Pharmaceutical media release, company announced Phesgo, a fixed-dose combination of Perjeta and Herceptin for subcutaneous injection, receives manufacturing and marketing approval for HER2-positive breast cancer and colorectal cancer and this approval is based on an international joint phase III clinical trial (FeDeriCa study) and (PHranceSCa study).
- 28 Oct 2022 Status changed from active, no longer recruiting to completed.